A broad-spectrum matrix metalloproteinase inhibitor prevents hemorrhagic complications induced by tissue plasminogen activator in mice

Neuroscience

Volumn 205, Issue , 2012, Pages 39-48

  Mishiro, K ^a   Ishiguro, M ^a   Suzuki, Y ^a   Tsuruma, K ^a   Shimazawa, M ^a   Hara, H ^a  

^a GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Blood brain barrier; GM6001; Matrix metalloproteinases; Tissue plasminogen activator

Indexed keywords

CLAUDIN 5; GELATINASE B; HEMOGLOBIN; ILOMASTAT; LACTATE DEHYDROGENASE; OCCLUDIN; PROTEIN ZO1; TISSUE PLASMINOGEN ACTIVATOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BLOOD VESSEL PERMEABILITY; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CELL DAMAGE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG MECHANISM; ELECTRIC RESISTANCE; ENZYME RELEASE; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOBLOTTING; IN VIVO STUDY; LOCOMOTION; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOLECULAR INTERACTION; MOLECULAR PATHOLOGY; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REOXYGENATION; REPERFUSION INJURY; SPECTROPHOTOMETRY; SURVIVAL RATE;

ANIMALS; ANIMALS, OUTBRED STRAINS; CEREBRAL HEMORRHAGE; DIPEPTIDES; DISEASE MODELS, ANIMAL; FIBRINOLYTIC AGENTS; MALE; MATRIX METALLOPROTEINASE 3; MATRIX METALLOPROTEINASE INHIBITORS; MICE; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84858008409     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2011.12.042     Document Type: Article

References (39)

1. Abbott N.J., Rönnbäck L., Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 2006, 7:41-53.
2. Ahdieh M., Vandenbos T., Youakim A. Lung epithelial barrier function and wound healing are decreased by IL-4 and IL-13 and enhanced by IFN-gamma. Am J Physiol Cell Physiol 2001, 281:C2029-C2038.
3. Asahi M., Asahi K., Jung J.C., del Zoppo G.J., Fini M.E., Lo E.H. Role for matrix metalloproteinase 9 after focal cerebral ischemia: effects of gene knockout and enzyme inhibition with BB-94. J Cereb Blood Flow Metab 2000, 20:1681-1689.
4. Ballabh P., Braun A., Nedergaard M. The blood-brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol Dis 2004, 16:1-13.
5. Bojarski C., Weiske J., Schöneberg T., Schröder W., Mankertz J., Schulzke J.D., Florian P., Fromm M., Tauber R., Huber O. The specific fates of tight junction proteins in apoptotic epithelial cells. J Cell Sci 2004, 117:2097-2107.
6. Chen W., Hartman R., Ayer R., Marcantonio S., Kamper J., Tang J., Zhang J.H. Matrix metalloproteinases inhibition provides neuroprotection against hypoxia-ischemia in the developing brain. J Neurochem 2009, 111:726-736.
7. Cheng T., Petraglia A.L., Li Z., Thiyagarajan M., Zhong Z., Wu Z., Liu D., Maggirwar S.B., Deane R., Fernández J.A., LaRue B., Griffin J.H., Chopp M., Zlokovic B.V. Activated protein C inhibits tissue plasminogen activator-induced brain hemorrhage. Nat Med 2006, 12:1278-1285.
8. del Zoppo G.J., Mabuchi T. Cerebral microvessel responses to focal ischemia. J Cereb Blood Flow Metab 2003, 23:879-894.
9. Dobrogowska D.H., Vorbrodt A.W. Immunogold localization of tight junctional proteins in normal and osmotically-affected rat blood-brain barrier. J Mol Histol 2004, 35:529-539.
10. Fukuda S., Fini C.A., Mabuchi T., Koziol J.A., Eggleston L.L., del Zoppo G.J. Focal cerebral ischemia induces active proteases that degrade microvascular matrix. Stroke 2004, 35:998-1004.
11. Giebel S.J., Menicucci G., McGuire P.G., Das A. Matrix metalloproteinases in early diabetic retinopathy and their role in alteration of the blood-retinal barrier. Lab Invest 2005, 85:597-607.
12. Grossetete M., Rosenberg G.A. Matrix metalloproteinase inhibition facilitates cell death in intracerebral hemorrhage in mouse. J Cereb Blood Flow Metab 2008, 28:752-763.
13. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. Stroke 1997, 28:2109-2118. Group Nr-PSS.
14. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995, 333:1581-1587. Group TNIoNDaSr-PSS.
15. Hacke W., Kaste M., Bluhmki E., Brozman M., Dávalos A., Guidetti D., Larrue V., Lees K.R., Medeghri Z., Machnig T., Schneider D., von Kummer R., Wahlgren N., Toni D. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008, 359:1317-1329.
16. Hansen H.P., Matthey B., Barth S., Kisseleva T., Mokros T., Davies S.J., Beckett R.P., Foelster-Holst R., Lange H.H., Engert A., Lemke H. Inhibition of metalloproteinases enhances the internalization of anti-CD30 antibody Ki-3 and the cytotoxic activity of Ki-3 immunotoxin. Int J Cancer 2002, 98:210-215.
17. Hao J.L., Nagano T., Nakamura M., Kumagai N., Mishima H., Nishida T. Galardin inhibits collagen degradation by rabbit keratocytes by inhibiting the activation of pro-matrix metalloproteinases. Exp Eye Res 1999, 68:565-572.
18. Hara H., Friedlander R.M., Gagliardini V., Ayata C., Fink K., Huang Z., Shimizu-Sasamata M., Yuan J., Moskowitz M.A. Inhibition of interleukin 1beta converting enzyme family proteases reduces ischemic and excitotoxic neuronal damage. Proc Natl Acad Sci U S A 1997, 94:2007-2012.
19. Hara H., Huang P.L., Panahian N., Fishman M.C., Moskowitz M.A. Reduced brain edema and infarction volume in mice lacking the neuronal isoform of nitric oxide synthase after transient MCA occlusion. J Cereb Blood Flow Metab 1996, 16:605-611.
20. Harkness K.A., Adamson P., Sussman J.D., Davies-Jones G.A., Greenwood J., Woodroofe M.N. Dexamethasone regulation of matrix metalloproteinase expression in CNS vascular endothelium. Brain 2000, 123(Pt 4):698-709.
21. Hirase T., Staddon J.M., Saitou M., Ando-Akatsuka Y., Itoh M., Furuse M., Fujimoto K., Tsukita S., Rubin L.L. Occludin as a possible determinant of tight junction permeability in endothelial cells. J Cell Sci 1997, 110(Pt 14):1603-1613.
22. Horstmann S., Kalb P., Koziol J., Gardner H., Wagner S. Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients: influence of different therapies. Stroke 2003, 34:2165-2170.
23. Ishiguro M., Mishiro K., Fujiwara Y., Chen H., Izuta H., Tsuruma K., Shimazawa M., Yoshimura S., Satoh M., Iwama T., Hara H. Phosphodiesterase-III inhibitor prevents hemorrhagic transformation induced by focal cerebral ischemia in mice treated with tPA. PLoS One 2010, 5:e15178.
24. Korninger C., Collen D. Studies on the specific fibrinolytic effect of human extrinsic (tissue-type) plasminogen activator in human blood and in various animal species in vitro. Thromb Haemost 1981, 46:561-565.
25. Lam C.K., Yoo T., Hiner B., Liu Z., Grutzendler J. Embolus extravasation is an alternative mechanism for cerebral microvascular recanalization. Nature 2010, 465:478-482.
26. Lee S.R., Kim H.Y., Rogowska J., Zhao B.Q., Bhide P., Parent J.M., Lo E.H. Involvement of matrix metalloproteinase in neuroblast cell migration from the subventricular zone after stroke. J Neurosci 2006, 26:3491-3495.
27. Mayne M., Ni W., Yan H.J., Xue M., Johnston J.B., Del Bigio M.R., Peeling J., Power C. Antisense oligodeoxynucleotide inhibition of tumor necrosis factor-alpha expression is neuroprotective after intracerebral hemorrhage. Stroke 2001, 32:240-248.
28. Montaner J., Molina C.A., Monasterio J., Abilleira S., Arenillas J.F., Ribó M., Quintana M., Alvarez-Sabín J. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation 2003, 107:598-603.
29. Rosenberg G.A. Matrix metalloproteinases in neuroinflammation. Glia 2002, 39:279-291.
30. Rosenberg G.A., Estrada E.Y., Mobashery S. Effect of synthetic matrix metalloproteinase inhibitors on lipopolysaccharide-induced blood-brain barrier opening in rodents: differences in response based on strains and solvents. Brain Res 2007, 1133:186-192.
31. Skiles J.W., Gonnella N.C., Jeng A.Y. The design, structure, and clinical update of small molecular weight matrix metalloproteinase inhibitors. Curr Med Chem 2004, 11:2911-2977.
32. Sumii T., Lo E.H. Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats. Stroke 2002, 33:831-836.
33. Tsuji K., Aoki T., Tejima E., Arai K., Lee S.R., Atochin D.N., Huang P.L., Wang X., Montaner J., Lo E.H. Tissue plasminogen activator promotes matrix metalloproteinase-9 upregulation after focal cerebral ischemia. Stroke 2005, 36:1954-1959.
34. Wang X., Jung J., Asahi M., Chwang W., Russo L., Moskowitz M.A., Dixon C.E., Fini M.E., Lo E.H. Effects of matrix metalloproteinase-9 gene knockout on morphological and motor outcomes after traumatic brain injury. J Neurosci 2000, 20:7037-7042.
35. Wang X., Tsuji K., Lee S.R., Ning M., Furie K.L., Buchan A.M., Lo E.H. Mechanisms of hemorrhagic transformation after tissue plasminogen activator reperfusion therapy for ischemic stroke. Stroke 2004, 35:2726-2730.
36. Wen H., Watry D.D., Marcondes M.C., Fox H.S. Selective decrease in paracellular conductance of tight junctions: role of the first extracellular domain of claudin-5. Mol Cell Biol 2004, 24:8408-8417.
37. Yong V.W. Metalloproteinases: mediators of pathology and regeneration in the CNS. Nat Rev Neurosci 2005, 6:931-944.
38. Youakim A., Ahdieh M. Interferon-gamma decreases barrier function in T84 cells by reducing ZO-1 levels and disrupting apical actin. Am J Physiol 1999, 276:G1279-G1288.
39. Zhao B.Q., Wang S., Kim H.Y., Storrie H., Rosen B.R., Mooney D.J., Wang X., Lo E.H. Role of matrix metalloproteinases in delayed cortical responses after stroke. Nat Med 2006, 12:441-445.